Emesis Control in Hematological-Oncology

References

• Laszlo J., Lucas V. S., Jr. Emesis as a critical problem in chemotherapy. N. Engl. J. Med. 1981; 305: 948–949
   PubMed Web of Science ®Google Scholar
• Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983; 25(Suppl 1)1–7
   PubMed Web of Science ®Google Scholar
• Coates A., Abraham S., Kaye S. B. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur. J. Cancer. Clin. Oncol. 1983; 19: 203–208
   PubMedGoogle Scholar
• Borison H. L., McCarthy L. E. Neuropharmacology of chemotherapy induced emesis. Drugs 1983; 25: 8–17
   PubMed Web of Science ®Google Scholar
• Andrews P. L. R., Rapeport W. G., Sanger G. J. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol. Sci 1988; 9: 334–341
   PubMed Web of Science ®Google Scholar
• Costall B., Domeney A. M., Naylor R. J., Tattersall F. D. 5-hydroxyhyptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 1986; 25: 959–961
   PubMed Web of Science ®Google Scholar
• Fozard J. R. 5-HT3 receptors and cytotoxic-induced vomiting. Trends Pharmacol. Sci 1987; 8: 44–45
   Web of Science ®Google Scholar
• Cubeddu L. X., Hoffmann I. S., Fuenmayor N. T., Finn A. L. Efficacy of ondansetron (GR 38032 F) and the role of serotonin in cisplatin-induced nausea and vomiting. 1990; 322: 810–816
   Google Scholar
• Gralla R. J., Clark R. A., Kris M. G., Tyson L. B. Methodology in anti-emetic trials. Eur J Cancer 1991; 27(Suppl 1)S5–S8
   PubMedGoogle Scholar
• Tonato M., Roila F., Del Favero A. Methodology of anti-emetic trials: a review. Ann. Oncol 1991; 2: 107–114
   PubMed Web of Science ®Google Scholar
• Gralla R. J., Tyson L. B., Kris M. G., Clark R. A. The management of chemotherapy-induced nausea and vomiting. Med. Clin. N. Amer. 1987; 71: 289–301
   PubMed Web of Science ®Google Scholar
• Kris M. G., Tyson L. B., Gralla R. J., et al. Extrapyramidal reactions with high-dose metoclopramide. N. Eng. J. Med. 1983; 309: 433
   PubMed Web of Science ®Google Scholar
• Allen J. C., Gralla R. J., Reilly, et al. Metoclopramide: dose related toxicity and preliminary anti-emetic studies in children receiving cancer chemotherapy. J. Clin. Oncol. 1985; 3: 1136–1141
   PubMed Web of Science ®Google Scholar
• d'Aquisito R. W., Tyson L. R., Gralla R. J., et al. The influence of a chronic alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 1986; 5: 257
   Google Scholar
• Fetting J. H., Wilcox P. M., Iwata B. A., et al. Anticipatory nausea and vomiting in an ambulatory medical oncology population. Cancer Treat Rep 1982; 66: 1601–1604
   PubMedGoogle Scholar
• Danjoux C. E., Rider W. D., Fitzpatrick P. J. The acute radiation syndrome. A memorial to William Michael Court-Brown. Clin Radiol 1979; 30: 581–584
   PubMed Web of Science ®Google Scholar
• Kris M. G., Gralla R. J., Clark R. A., et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379–1384
   PubMed Web of Science ®Google Scholar
• Nerenz D. R., Leventhal H., Easterling D. V., et al. Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy. J. Clin. Oncol 1986; 4: 224–233
   PubMed Web of Science ®Google Scholar
• Morrow G. R., Morrell C. Behavioural treatment for anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982; 307: 1476–1480
   PubMed Web of Science ®Google Scholar
• Kris M. G., Gralla R. J., Clark R. A., et al. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide + dexamethazone over the combination of diphenhydramine + metoclopramide + dexamethazone. Cancer Treat Rep 1985; 69: 1257–1262
   PubMedGoogle Scholar
• Kidgell A. E., Butcher M. E., Brown G. W. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron. Cancer Treat Rev 1990; 17: 311–317
   PubMed Web of Science ®Google Scholar
• Pintens H. Granisetron (BRL 43694) in the treatment of drug-induced emesis: summary. Cancer Treat Rev 1990; 17: 307–310
   PubMed Web of Science ®Google Scholar
• Gamse R. Anti-emetic action of 5-HT3 receptor antagonists: review of preclinical and clinical results with ICS 205–930. Cancer Treat Rev 1990; 17: 301–305
   PubMed Web of Science ®Google Scholar
• Smaldone L., Plezia P., Alberts D., et al. Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis. Cancer Treat Rev 1990; 17: 318–327
   Web of Science ®Google Scholar
• Marty M., Pouillart P., Scholl S., et al. Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816–821
   PubMed Web of Science ®Google Scholar
• De Mulder P., Seynaeve C., Vermorken J., et al. Ondansetron compared with high-dose metoclopramide in the prophylasis of acute and delayed cisplatin-induced nausea and vomiting-a multicentre, randomized, double-blind, crossover study. Ann Intern Med 1990; 113: 834–840
   PubMed Web of Science ®Google Scholar
• Hainsworth J., Harvey W., Pendergrass K., et al. A single-blind comparison oif intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J. Clin Oncol 1991; 9: 721–728
   PubMed Web of Science ®Google Scholar
• Kaasa S., Kvaloy S., Dicato M. A., et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J. Cancer 1990; 26: 311–314
   PubMed Web of Science ®Google Scholar
• Bonneterre J., Chevalier B., Metz R., et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracile and doxurubicin or epirub-icin chemotherapy. J Clin Oncol 1990; 8: 1063–1069
   PubMed Web of Science ®Google Scholar
• Stevens R. F. The role of ondansetron in paediatric patients: a review of three studies. Eur J Cancer 1991; 27(suppl 1)S20–S22
   PubMedGoogle Scholar
• Dicato M. A. Oral treatment with ondansetron in an outpatient setting. Eur J Cancer 1991; 27(Suppl 1)S18–S19
   PubMedGoogle Scholar
• Brown G. W. (1991) Ondansetron: simplified dosing schedules. Proceedings Ondansetron Satellite Symposium, Florence, Nov, 1991, ECCO Meeting
   Google Scholar
• Carden P. A., Mitchell S. L., Waters K. D., et al. Prevention of cyclophosphamide/cytarabine induced emesis in children with leukemia. J. Clin. Oncol 1990; 8: 1531–1533
   PubMed Web of Science ®Google Scholar
• Rodjer S., Mercke C., van Imhoff G., et al. A randomized, double-blind, placebo-controlled study of ondansetron against CHOP-induced emesis. Proceedings ECCO 5, Florence, 1991
   Google Scholar
• Gisselbrecht C., Harousseau J-L., Paillarse J-M. A multicentre study to compare the efficacy and safety of ondansetron with alizapride in the prophylaxis of emesis induced by chemotherapy of lymphoma. Proceedings ECCO 5, Florence, 1991
   Google Scholar
• Priestman T. J. Clinical studies with ondansetron in the control of radiation-induced emesis. Eur J Cancer Clin Oncol 1989; 25(Suppl 1)S29–S33
   PubMedGoogle Scholar
• Croockewit S. (1990) The efficacy of Ondansetron in emesis induced by total body irradiation. Copenhagen Ondansetron satellite symposium. Dec, 21990. Copenhagen Falkoner Center, 15–17
   Google Scholar
• Tonato M. Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. Eur J Cancer 1991; 27(Suppl 1)S12–S14
   PubMedGoogle Scholar
• Gandara D. R. Progress in the control of acute and delayed emesis induced by cisplatin. Eur. J Cancer 1991; 27(Suppl 1)S9–S11
   PubMedGoogle Scholar
• Upward J. W., Arnold B. D. C., Link C., et al. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur] Cancer 1990; 26(Suppl 1)S12–S15
   PubMed Web of Science ®Google Scholar
• Tabona M. V. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy. Eur J Cancer 1990; 26(Suppl 1)S37–S41
   PubMedGoogle Scholar
• Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur] Cancer 1990; 26(Suppl 1)S15–S19
   PubMed Web of Science ®Google Scholar
• Smith I. E. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 1990; 26(Suppl 1)S19–S23
   PubMedGoogle Scholar
• Cupissol D. R., Serrou B., Caubel M. The efficacy of granistron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990; 26(Suppl 1)S23–S27
   PubMed Web of Science ®Google Scholar
• Marty M. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard antiemetic regimen of chlorpromazine plus dexamethazone in the treatment of cytostatic-induced emesis. Eur J Cancer 1990; 26(Suppl 1)S28–S32
   PubMedGoogle Scholar
• Chevalier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethazone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 1990; 26(Suppl 1)S33–S36
   PubMedGoogle Scholar